PERTH, Australia--(BUSINESS WIRE)--Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or
the “Company”) is pleased to announce that it has commenced treatment of
its 1,000th patient, in its TGA licensed manufacturing
facility using the Company’s proprietary tissue engineering process,
developed in conjunction with Professor Minghao Zheng and the University
of Western Australia. This marks a significant milestone in the
Company’s history as it continues to clinically validate its market
leading regenerative medicine technologies and drive entry into the US,
the world’s largest healthcare market.

Orthocell’s Managing Director Paul Anderson commented: “This
is a significant milestone in the development of Orthocell’s cell
therapies, providing strong clinical data and in-market validation of
the safety and effectiveness of our technologies for the repair and
regeneration of soft tissue.This achievement is expected to
support ongoing global commercialisation efforts.”

Orthocell’s Ortho-ATI® and Ortho-ACI® for tendon and cartilage repair
are breakthrough technologies addressing the underlying pathology of
tendon and cartilage injuries. The treatments accelerate the
regeneration of injured tendons and cartilage and allows patients to
return to recreational activities, the workplace and competitive sports.
Christian Sprenger, a former Australian Olympic swimmer, who sustained a
severe shoulder injury in 2014, was only able to compete at an elite
level again after receiving Orthocell’s Ortho-ATI® treatment.

“I am 100% happy with the Ortho-ATI® treatment, it’s the only thing
that enabled me to get back to doing normal daily activities.It
definitely helped me, I can do everything now that I want to do with
full function and without pain.Following Ortho-ATI®, I was able
to return to swimming at an international level,”saidChristian
Sprenger.

Orthocell’s published clinical data and annual patient satisfaction
surveys conducted to date have shown reduction in symptoms, return to
function and high levels of patient satisfaction. Orthocell’s cell
therapies for tendon and cartilage repair are available in Australia,
New Zealand, Hong Kong and Singapore.

About Ortho-ATI®:

Ortho-ATI® is a world leading breakthrough in regenerative medicine – a
novel, cell therapy developed to treat chronic degenerative tendon
injuries (tendinopathy / tendonitis), it can be utilised in both
surgical and non-surgical applications.

Tendon injury and its end point, tendinopathy, are a common cause of
occupational and sporting disability reported to affect 1% to 3% of
the general population every year

Significant financial burden to the public health care system expected
to increase as the population ages, as a result, new treatments are
required that are safe, effective and cost efficient

Extensive clinical validation with published clinical data up to 4.5
years post treatment in leading peer reviewed journals, (e.g. American
Journal Sports Medicine) clearly demonstrating durability and
efficacy as the leading tendon regeneration treatment

About Ortho-ACI®:

Ortho-ACI® is the gold standard intervention for symptomatic defects of
the articulating cartilage of the joints, predominately the knee and
ankle.

Damage to articular cartilage can occur through injury or normal wear
and tear affecting activities of daily living and exercise. These
defects present a difficult clinical problem and if left untreated can
lead to osteoarthritis

Ortho-ACI® provides the opportunity for the body to regenerate its own
cartilage and provides a functional and durable outcome

Ortho-ACI® is positioned as the highest quality cartilage repair
product available today with superior cost effectiveness when compared
to alternatives